BIOVIE INC.
Close on Oct 19, 2026
- Market cap
- $10.86M
- P/E (TTM)
- –
- Dividend yield
- –
About Biovie
Pharmaceutical Preparations, SIC 2834
BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for neurological and neurodegenerative disorders as well as advanced liver disease. Its neurodegenerative pipeline centers on bezisterim (NE3107), an investigational, orally administered small molecule designed to inhibit neuroinflammation and insulin resistance in conditions such as Parkinson’s disease, Alzheimer’s disease, and long COVID. In liver disease, the company develops BIV201, a continuous infusion liquid formulation of terlipressin targeting ascites and complications of liver cirrhosis. Because its therapeutic candidates remain under clinical investigation, the company does not have commercial products or regular commercial customers.
The company operates in the United States and maintains intellectual property and clinical development activities across international jurisdictions, holding patents in countries such as the United States, Canada, Europe, China, Japan, Australia, Chile, and Mexico. BioVie Inc. maintains its principal executive offices in Carson City, Nevada.
Summary of the business section of Biovie's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BIOVIE INC.
- Headquarters
- Carson City, NV
- Address
- 680 W Nye Lane, Suite 201 89703
- Phone
- (775) 888-3162
- Website
- bioviepharma.com
- Employees
- 13, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- June 30
- Auditor
- EisnerAmper LLP, Iselin
Stock & identifiers
- Ticker
- BIVI
- Other tickers
- BIVIW
- Exchange
- Nasdaq
- IPO date
- Sep 18, 2020
- Shares outstanding
- 8M, Aug 10, 2026
- Public float
- $8.45M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Jul 7, 2025; 1-for-10 reverse, Aug 6, 2024; 1-for-125 reverse, Feb 13, 2020
- SEC CIK
- 1580149
- CUSIP
- 09074F504
- ISIN
- US09074F5044
- EIN
- 46-2510769
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Cuong V. Do | President & CEO, Director | 26,109 |
| Joseph M. Palumbo | Chief Medical Officer | 6,036 |
| Joanne Wendy Kim | Chief Financial Officer | 5,441 |
| Amy Suzon Chappell | Director | 727 |
| Sigmund Rogich | Director | 36,926 |
| Kameel D. Farag | Director | – |
| James Paul Lang | Director | 68,622 |
| Michael Edward Sherman | Director | 20,679 |
| Robert J. Hariri | Director | 42,254 |
| Richard J. Berman | Director | 40,643 |
Employees
Headcount reported in annual reports
“Company has 13 employees which are all full time.”
Corporate history
Events identified from SEC filings